Salix announced the availability of Xifaxan 550 in a new two-week treatment Pack. The Xifaxan two-week Pack contains 42 tablets, providing a full course of treatment for irritable bowel syndrome with diarrhea (IBS-D).
Targeting the bacteria Helicobacter pylori with a short course of combination therapy may help decrease the risk of gastric cancer.
In a new study, some patients with advanced ulcerative colitis (UC) had better outcomes with elective colectomy compared to immunosuppressant therapy, even though this is typically a treatment of last resort.
The Food and Drug Administration (FDA) announced that Emend (aprepitant; Merck) is currently in shortage.
Use of proton pump inhibitors (PPIs) increase the risk of an adult experiencing a heart attack by 16-21% compared to those who don't use commonly prescribed antacids, a large study has found.
The FDA has approved Viberzi (eluxadoline; Actavis) and Xifaxan 550mg (rifaximin; Salix) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
A non-aggressive Clostridium difficile strain significantly reduced the risk of Clostridium difficile infection (CDI) recurrence in a small study published in the Journal of the American Medical Association.
In the first study to assess the use of the relaxation response for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), a nine-week training program including use of the relaxation response had a significant impact on the clinical symptoms of these disorders.